These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Daptomycin: a new drug class for the treatment of Gram-positive infections. Alder JD Drugs Today (Barc); 2005 Feb; 41(2):81-90. PubMed ID: 15821781 [TBL] [Abstract][Full Text] [Related]
3. Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens. Carpenter CF; Chambers HF Clin Infect Dis; 2004 Apr; 38(7):994-1000. PubMed ID: 15034832 [TBL] [Abstract][Full Text] [Related]
4. Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections. Steenbergen JN; Alder J; Thorne GM; Tally FP J Antimicrob Chemother; 2005 Mar; 55(3):283-8. PubMed ID: 15705644 [TBL] [Abstract][Full Text] [Related]
5. The efficacy and safety of daptomycin: first in a new class of antibiotics for Gram-positive bacteria. Rybak MJ Clin Microbiol Infect; 2006 Mar; 12 Suppl 1():24-32. PubMed ID: 16445721 [TBL] [Abstract][Full Text] [Related]
6. The use of daptomycin for Staphylococcus aureus infections in critical care medicine. Alder J Crit Care Clin; 2008 Apr; 24(2):349-63, ix-x. PubMed ID: 18361950 [TBL] [Abstract][Full Text] [Related]
8. Management of cSSTIs: the role of daptomycin. Garau J Curr Med Res Opin; 2006 Nov; 22(11):2079-87. PubMed ID: 17076967 [TBL] [Abstract][Full Text] [Related]
9. [Role of daptomycin in the empirical and directed therapy of infections caused by Gram-positive bacteria in the critically ill patient]. Garnacho-Montero J; Amaya-Villar R; Gómez-Grande ML; Jerez V; Lorente-Ramos L; Loza A; Martínez A; Pozo JC; Sierra R; Pomares J; de la Torre MV; Ortiz C Rev Esp Quimioter; 2011 Mar; 24(1):13-24. PubMed ID: 21412665 [TBL] [Abstract][Full Text] [Related]
10. Daptomycin, a lipopeptide antibiotic in clinical practice. Weis F; Beiras-Fernandez A; Schelling G Curr Opin Investig Drugs; 2008 Aug; 9(8):879-84. PubMed ID: 18666036 [TBL] [Abstract][Full Text] [Related]
14. Antimicrobial activity of daptomycin tested against gram-positive strains collected in European hospitals: results from 7 years of resistance surveillance (2003-2009). Sader HS; Farrell DJ; Jones RN J Chemother; 2011 Aug; 23(4):200-6. PubMed ID: 21803696 [TBL] [Abstract][Full Text] [Related]
15. Daptomycin: a rapidly bactericidal lipopeptide for the treatment of Gram-positive infections. Kanafani ZA; Corey GR Expert Rev Anti Infect Ther; 2007 Apr; 5(2):177-84. PubMed ID: 17402833 [TBL] [Abstract][Full Text] [Related]
16. Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004). Biedenbach DJ; Bell JM; Sader HS; Fritsche TR; Jones RN; Turnidge JD Int J Antimicrob Agents; 2007 Aug; 30(2):143-9. PubMed ID: 17531446 [TBL] [Abstract][Full Text] [Related]
18. Daptomycin in the treatment of skin, soft-tissue and invasive infections due to Gram-positive bacteria. Johnson A Future Microbiol; 2006 Oct; 1(3):255-65. PubMed ID: 17661638 [TBL] [Abstract][Full Text] [Related]
19. Activity of dalbavancin tested against Gram-positive clinical isolates causing skin and skin-structure infections in paediatric patients from US hospitals (2014-2015). Pfaller MA; Mendes RE; Sader HS; Castanheira M; Flamm RK J Glob Antimicrob Resist; 2017 Dec; 11():4-7. PubMed ID: 28735053 [TBL] [Abstract][Full Text] [Related]
20. A current perspective on daptomycin for the clinical microbiologist. Humphries RM; Pollett S; Sakoulas G Clin Microbiol Rev; 2013 Oct; 26(4):759-80. PubMed ID: 24092854 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]